Dana-Farber’s Bank of Patient-Derived Tumor Xenografts Gets Major Boost From Novartis

Dana-Farber Cancer Institute is establishing a bank of patient-derived xenograft models of more than 750 human tumors.
7-Mar-2018 5:00 AM EST Add to Favorites

Cognitive Decline Prevalent Among Elderly Patients with Hematologic Cancers, Study Finds

A sizable percentage of elderly patients with blood-related cancers such as leukemia and multiple myeloma are apt to show signs of diminished cognitive functioning
6-Mar-2018 11:05 AM EST Add to Favorites

Discovery Suggests New Strategy for Attacking High- Profile but Elusive Target in Cancer

A discovery by scientists at Dana-Farber Cancer Institute and University of Texas Southwestern Medical Center presents drug developers with an entirely new tack in targeting one of the most-wanted molecular culprits in cancer.
11-Jan-2018 1:00 PM EST Add to Favorites

Mechanism for Resistance to Immunotherapy Treatment Discovered

Two research groups from Dana-Farber Cancer Institute have independently discovered a genetic mechanism in cancer cells that influences whether they resist or respond to immunotherapy drugs known as checkpoint inhibitors. The scientists say the...
3-Jan-2018 2:50 PM EST Add to Favorites

Dana-Farber/Brigham and Women’s physician wins prestigious 2017 William Dameshek Prize from the American Society of Hematology

• Benjamin Ebert, MD, PhD, current chair of Medical Oncology, was presented with recognition at annual American Society of Hematology meeting • Ebert is notable for his leadership in describing the genomic landscape of adult myelodysplastic...
7-Dec-2017 2:30 PM EST Add to Favorites

Study Identifies Agent That Can Reverse Resistance to Targeted Drug in Some Leukemia Cell Types

• Azacitidine reverses resistance to SL-401 in AML and BPDCN cell lines, researchers find • Results prompt clinical trial of SL-401 and azacitidine in AML and MDS patients
7-Dec-2017 2:30 PM EST Add to Favorites

Study Shows Combining Chemotherapy with Targeted Drug Boosts Response in Chronic Lymphocytic Leukemia

Among younger patients newly diagnosed with chronic lymphocytic leukemia (CLL), treatment with a combination of chemotherapy and a molecularly targeted drug significantly improves response over what is typically seen with chemotherapy alone,...
7-Dec-2017 2:25 PM EST Add to Favorites

Sequencing Offers Clues to Progression Toward Multiple Myeloma

Researchers at Dana-Farber Cancer Institute have carried out the largest genomic analysis of patients with smoldering multiple myeloma (SMM), a precursor to full-blown blood cancer that doesn’t show outward symptoms.
7-Dec-2017 2:30 PM EST Add to Favorites